Abstract: . . .  L, Frommer M. A schema for evaluating evidence on public health interventions; version 4. Melbourne: National Public Health Partnership, 2002; Appendix 1. Available at: http://www.nphp.gov.au/ppi/evidence/schema/ appendix1.htm (accessed Apr 2003). 24. Rich S, Dodin E, McLaughlin V, et al. Usefulness of atrial septostomy as a treatment for primary pulmonary hypertension and guidelines for its application. Am J Cardiol 1997; 80: 369-371. (Received 22 Oct 2002, accepted 27 Mar 2003) ?  . . .
. . .  #2179. 12. Simmoneau G, Barst R, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hyperten- sion. Am J Respit Crit Care Med 2002; 165: 800-804. 13. Gali N, Humbert M, Wachiery JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension : a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002; 39: 1496-1502. 14. Olchewski H, Ghofrani H, Schmehl T, et al. Inhaled iloprost to treat severe pulmonary hypertension : an uncontrolled trial. Ann Intern Med 2000; 132: 435- 443. 15. Evans TW, Gatzoulis MA, Gibbs JSR. A national pulmonary . . .
. . .  effective oral agents, we can abandon the therapeutic nihilism of past decades, and offer patients effective therapies. Some of these agents allow reverse remodelling of the right ventricle within very short periods. Reverse remodelling of the pulmonary artery and the potential to reverse the entire disease process are realistic targets. This new era of effective agents gives clinicians a sound reason to diagnose PAH, to tease out all contributing elements and to detect cases early. Trials to date have been performed in moderately to severely affected patients, but are now in progress in less ill patients. As with most cardiovascular diseases, earlier detection and intervention is likely . . .
. . .  pulmonary hypertension . N Engl J Med 1996; 334: 296-301. 18. Barst RJ, Rubin LJ, McGoon MD, et al. Survival in primary pulmonary hyperten- sion with long-term continuous intravenous prostacyclin. Ann Intern Med 1994; 121: 409-415. 19. McLaughlin V, Shillington A, Rich S. Survival in primary pulmonary hypertension : the impact of epoprostenol therapy. Circulation 2002; 106: 1477-1482. 20. Wilkens H, Guth A, Konig J, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension . Circulation 2001; 104: 1218-1222. 21. Sastry B, Narasimhan C, Reddy N, et al. A study of clinical efficacy of sildenafil inpatients with primary pulmonary hypertension . Indian . . .
--3000,4,375,3096,22311